JPWO2022192694A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022192694A5
JPWO2022192694A5 JP2023555565A JP2023555565A JPWO2022192694A5 JP WO2022192694 A5 JPWO2022192694 A5 JP WO2022192694A5 JP 2023555565 A JP2023555565 A JP 2023555565A JP 2023555565 A JP2023555565 A JP 2023555565A JP WO2022192694 A5 JPWO2022192694 A5 JP WO2022192694A5
Authority
JP
Japan
Prior art keywords
protein
fold
item
subject
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024510215A5 (https=
JP2024510215A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/019984 external-priority patent/WO2022192694A1/en
Publication of JP2024510215A publication Critical patent/JP2024510215A/ja
Publication of JP2024510215A5 publication Critical patent/JP2024510215A5/ja
Publication of JPWO2022192694A5 publication Critical patent/JPWO2022192694A5/ja
Pending legal-status Critical Current

Links

JP2023555565A 2021-03-12 2022-03-11 タンパク質発現のための系及び方法 Pending JP2024510215A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163160672P 2021-03-12 2021-03-12
US63/160,672 2021-03-12
PCT/US2022/019984 WO2022192694A1 (en) 2021-03-12 2022-03-11 Systems and methods for protein expression

Publications (3)

Publication Number Publication Date
JP2024510215A JP2024510215A (ja) 2024-03-06
JP2024510215A5 JP2024510215A5 (https=) 2025-03-19
JPWO2022192694A5 true JPWO2022192694A5 (https=) 2025-03-19

Family

ID=83228345

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555565A Pending JP2024510215A (ja) 2021-03-12 2022-03-11 タンパク質発現のための系及び方法

Country Status (11)

Country Link
US (1) US20240141373A1 (https=)
EP (1) EP4305176A4 (https=)
JP (1) JP2024510215A (https=)
KR (1) KR20230169989A (https=)
CN (1) CN117321209A (https=)
AU (1) AU2022235284A1 (https=)
BR (1) BR112023018404A2 (https=)
CA (1) CA3211755A1 (https=)
IL (1) IL305817A (https=)
MX (1) MX2023010658A (https=)
WO (1) WO2022192694A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3153942A1 (en) * 2019-09-16 2021-03-25 Excepgen Inc. Systems and methods for protein expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7741022B2 (en) * 2006-01-18 2010-06-22 Wisconsin Alumi Research Foundation Protein inhibitor of Ran activity and methods of use thereof
KR20140071452A (ko) * 2006-04-05 2014-06-11 애브비 바이오테크놀로지 리미티드 항체 정제
AU2007241622A1 (en) * 2006-04-24 2007-11-01 Academisch Medisch Centrum Improved treatment of cystic fibrosis
CN104114572A (zh) * 2011-12-16 2014-10-22 现代治疗公司 经修饰的核苷、核苷酸和核酸组合物
US12590321B2 (en) * 2016-03-19 2026-03-31 Exuma Biotech Corp. Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof
FR3081169B1 (fr) * 2018-05-15 2020-06-19 Messenger Biopharma Substitution de la coiffe des arn messagers par deux sequences d'arn introduites a leur extremite 5'
KR20220012231A (ko) * 2019-04-24 2022-02-03 리젠엑스바이오 인크. 완전-인간 번역 후 변형된 항체 치료제
CA3153942A1 (en) * 2019-09-16 2021-03-25 Excepgen Inc. Systems and methods for protein expression

Similar Documents

Publication Publication Date Title
JP3515111B2 (ja) 哺乳動物細胞における複シストロンベクター系を用いるヘテロダイマーｐｄｇｆ−ａｂの調製
US5766897A (en) Cysteine-pegylated proteins
AU2009223115B2 (en) Recombinant production of authentic human proteins using human cell expression systems
US6482618B2 (en) Self-enhancing, pharmacologically controllable expression systems
US20120322730A1 (en) Methods and compositions for the prevention and treatment of anemia
MXPA02010333A (es) Metodos y composiciones para la prefencion y tratamiento de anemia.
JPWO2020033863A5 (https=)
KR20080017362A (ko) 창상 치유를 위한 ｖｅｇｆ의 용도
FR2832716A1 (fr) Proteine de fusion ayant augmente l'activite in vivo de l'erythroproietine
JP4280786B2 (ja) 同一のｎ末端を有する塩基性繊維芽細胞増殖因子の高レベル発現
JPWO2022192694A5 (https=)
US20040053368A1 (en) Collagen-binding hybrid polypeptide
AU1378897A (en) New form of amphiregulin, methods for producing and using the same and compositions comprising the same
CN113785067B (zh) 氯化物诱导型原核表达系统
US20230340499A1 (en) Constructs, compositions, cells and methods for increased recombinant protein expression by targeted integration and amplification
AU2009354779A1 (en) Recombinant production of authentic human proteins using human cell expression systems
JP2002060400A (ja) コラーゲン結合活性および血管新生調節活性を有するハイブリッドポリペプチド
WO2022192687A1 (en) Synthetic promoters for gene therapy and protein expression
Nazemi Zadeh et al. Lab-scale Production of Recombinant Platelet-derived Growth Factor-BB Homodimer (PDGF-BB) in Microbial Expression System
CN118574931A (zh) 一种新型5’-非翻译区元件及其应用
CA3223116A1 (en) Constructs, compositions, cells and methods for increased recombinant protein expression by targeted integration and amplification
CN119384507A (zh) 用于以rna表达蛋白质的组合物和方法
ANTHONY Affecting Biopharmaceutical Quality
RU2021105649A (ru) Молекулы нуклеиновой кислоты и пути их применения для невирусной генной терапии
Lubiniecki Fermentation process events affecting biopharmaceutical quality